CTL Medical will acquire the commercial spine business of Amedica (AMDA) via asset purchase agreement for US $10.0MM. The transaction is slated to close within 3Q18. For 2017, AMDA posted product revenue of 11.2MM, -26% vs. 2016.
CTL will exclusively own the portfolio of AMDA’s metal and silicon nitride (SiNi) spine devices, and will have access to future SiNi spine products. CTL gains the entire existing inventory of Taurus, Preference and Valeo products, along with global regulatory clearances and IP. Manufacturing, R&D and all IP related to SiNi’s core biomaterial technology will remain with AMDA, which will be CTL’s exclusive provider of SiNi products.
CTL produces a full line of cervical, thoracic and lumbar products, and intends to apply attributes of SiNi across its entire portfolio.
CTL Medical will change its name to CTL Amedica, and AMDA will choose a new name and focus on non-spine applications. As noted in its 2017 10-K, the company believes that the silicon nitride material addresses many biomaterial-related limitations in fields such as hip and knee replacements, dental implants, sports medicine, extremities, and trauma surgery.
CTL Medical will acquire the commercial spine business of Amedica (AMDA) via asset purchase agreement for US $10.0MM. The transaction is slated to close within 3Q18. For 2017, AMDA posted product revenue of 11.2MM, -26% vs. 2016.
CTL will exclusively own the portfolio of AMDA's metal and silicon nitride (SiNi) spine devices, and will have...
CTL Medical will acquire the commercial spine business of Amedica (AMDA) via asset purchase agreement for US $10.0MM. The transaction is slated to close within 3Q18. For 2017, AMDA posted product revenue of 11.2MM, -26% vs. 2016.
CTL will exclusively own the portfolio of AMDA’s metal and silicon nitride (SiNi) spine devices, and will have access to future SiNi spine products. CTL gains the entire existing inventory of Taurus, Preference and Valeo products, along with global regulatory clearances and IP. Manufacturing, R&D and all IP related to SiNi’s core biomaterial technology will remain with AMDA, which will be CTL’s exclusive provider of SiNi products.
CTL produces a full line of cervical, thoracic and lumbar products, and intends to apply attributes of SiNi across its entire portfolio.
CTL Medical will change its name to CTL Amedica, and AMDA will choose a new name and focus on non-spine applications. As noted in its 2017 10-K, the company believes that the silicon nitride material addresses many biomaterial-related limitations in fields such as hip and knee replacements, dental implants, sports medicine, extremities, and trauma surgery.
Copy to clipboard 
